MA-ICURE-PHARMACEUTICAL
16.11.2021 15:03:14 CET | Business Wire | Press release
Icure Pharmaceutical Inc. (KOSDAQ: 175250), a biopharmaceutical company in Korea, announced today that its donepezil patch, a treatment of Alzheimer’s-type dementia, received a drug product approval from the Ministry of Food and Drug Safety of Korea.
The drug product approval process took 7 months after it filed an application in April 2021. With the approval, Icure marks the first commercialization of the donepezil patch in the world.
Donepezil is a current typical treatment that has been widely prescribed for the longest period for Alzheimer’s disease patients in severity ranging from mild to moderate and severe ones among FDA-approved Alzheimer's treatments. Due to difficulty in the development of its formulations, donepezil has been commercialized for only oral administration to date.
With successful completion of a Phase III clinical trial for the first time in the world, the donepezil patch of Icure is expected to significantly improve the quality of life of patients with Alzheimer’s-type dementia and their caregivers by enhancing the convenience in its use from orally taking once daily to putting a patch on skin twice a week.
With nearly 400 mild and moderate dementia patients in Korea, Taiwan, Australia and Malaysia, Icure successfully conducted a Phase III clinical study for its donepezil patch. Specifically, the study demonstrated noninferiority compared to oral donepezil in Alzheimer's disease assessment scale cognitive subscale (ADAS-cog), a typical standard tool for evaluating abilities of memory, language, reorganization, action and orientation in patients with mild and moderate Alzheimer’s-type dementia.
“Based on outstanding efficacy and marketability of donepezil along with our technological prowess, we expect our donepezil patch will sufficiently take over the market of donepezil oral products as we have seen a high conversion rate of rivastigmine patches in the past,” said CEO YoungKweon Choi, Ph.D. of Icure, who led donepezil patch development. “We reported results of the Phase III clinical trial of donepezil patch at the Conference on Clinical Trials of Alzheimer’s Disease (CTAD) that was held on November 9~12, 2021 in Boston, Massachusetts.” He attended the CTAD Conference to present the results of the clinical study while making consultations on potential global transactions.
Now that its donepezil patch received FDA approval for Phase I clinical trial as an investigational new drug in April 2021, Icure will start to administer it to patients in the latter part of 2022. The company expects to begin in 2025 to provide the donepezil patch in the global market by reducing the period of clinical trials through the 505(b)2 clinical study track. Today, the global dementia treatments market is estimated to reach around USD 3 billion, and it is anticipated to increase to roughly USD 5 billion by 2024 as the world transforms into an aging society. Icure plans to expand the global business of transdermal drug delivery system (TDDS) as its production facilities in Wanju, Korea obtained the cGMP certification.
Starting with the donepezil patch, Icure diversifies pipelines by developing a variety of DDS-based incrementally modified drugs and new drugs. Following the donepezil patch, the company is developing a pramipexole patch that will be used for treating Parkinson’s disease. And Icure BNP, a subsidiary of Icure, is currently developing oral liraglutide peptide formulation from injectable liraglutide peptide product that is being used for treating diabetes and obesity while accelerating the development of microneedles and lipid-based nanoparticle (LNP) drugs through CuRsuS Bio and EBA BIO. In addition, Icure is also in the development of the world’s first oral peptide-based anticancer drug and a new drug based on PROTAC through oneCureGen and Dandi Cure, attracting attention on the potentiality of growing into a global pharmaceutical company by developing varied DDS-based new drugs.
For more information on Icure Pharmaceutical Inc., visit https://icure.co.kr .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005684/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Announces Appointment of New Chief Financial Officer16.2.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization. “Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership in dermatology. I would also like to thank Thomas for his commitment to ensuring a seamless transition
REJO brings CUBE modular device to Japan in its global premiere16.2.2026 03:00:00 CET | Press release
FlexiCUBE™, the world’s first modular heat-not-burn device, offers adult users customizable color combinations OmniHeat™ 360° technology elevates consistent aerosol performance to new levels Puff Twice feature enables a second heating cycle for auto-heat HNB sticks, allowing adult users access more value from every stick REJO, a pioneering global provider of heat-not-burn (HNB) solutions, today announced the global debut of REJO CUBE, its latest modular HNB device, in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215596376/en/ REJO CUBE DEVICE-Product Infographic Breaking away from conventional HNB design norms, REJO CUBE introduces a bold new device option featuring a trendy design and dual-mode inhalation experience, launching on Japan’s major e-commerce retail channels from February 16. This launch marks the brand’s latest move following REJO Mate Air’s introduction in Japan in July 2025, when the device’s comp
Sultan bin Ahmed Visits Shanghai Film Studios, Film Park and Stadium15.2.2026 20:24:00 CET | Press release
His Highness Sheikh Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, visited the 800,000-square-metre Shanghai Film Studios and Film Park in the town of Shidon in the Chinese city of Shanghai on Saturday. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215440594/en/ Sultan bin Ahmed visits Shanghai Film Studios, Film Park and Stadium (Photo: AETOSWire) His Highness watched a video outlining the specifications of the Shanghai studios, which comprise 4 professional studios ranging in size from 800 to 3000 square metres, a large costume warehouse, production support facilities, classic cars, and an integrated set of production services. His Highness was briefed on the work produced using artificial intelligence technologies. He toured the sound recording rooms, image quality control, editing and post-production facilities, and listened to an explanation on the developme
Estithmar Holding Establishes “Estithmar Capital” for Financial Investment Management15.2.2026 18:45:00 CET | Press release
Estithmar Holding Q.P.S.C. announced today the establishment of its fifth group, “Estithmar Capital,” in a strategic step aimed at strengthening the company’s expansion and diversifying the sectors in which it operates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215458570/en/ Estithmar Holding Establishes “Estithmar Capital” for Financial Investment Management (Photo: AETOSWire) Estithmar Capital will specialize in managing financial investments, strengthening institutional governance, and operating under clear frameworks for compliance, regulation, and risk management, reflecting Estithmar Holding’s vision for sustainability and responsible, well-structured growth. The establishment of Estithmar Capital supports Estithmar Holding’s broader strategy of diversifying financial assets, improving capital efficiency, and unifying governance practices across various markets. Through a centralized and disciplined approach, t
Align Partners Issues Third Public Shareholder Letter and Submits Formal Shareholder Proposals to Coway14.2.2026 12:31:00 CET | Press release
Align Partners highlights Coway’s persistent undervaluation despite steady global growth, citing structural ROE decline as a key driver Align Partners urges the Board to address inefficient capital structure and strengthen shareholder return discipline; requests a formal response by March 13, 2026 The proposals call for stronger Board independence, enhanced Audit Committee oversight, and improved compensation transparency Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Coway Co., Ltd. (“Coway” or the “Company”), has submitted formal shareholder proposals for the Company’s upcoming 37th Annual General Meeting (“AGM”) and issued its third public shareholder letter to Coway’s Board of Directors. Coway is South Korea’s leading home appliance rental platform, supported by a strong global brand and sales network. Since Netmarble became the largest shareholder in 2020, Coway has delivered steady operating growth, with revenue and operating profit increasing at comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom